[{"id":"7d4f5eec-d35e-4cf9-94e4-4da7039b90db","acronym":"","url":"https://clinicaltrials.gov/study/NCT01300962","created_at":"2021-01-18T05:17:21.485Z","updated_at":"2025-02-25T15:51:43.149Z","phase":"Phase 1","brief_title":"Study of BKM120 or BYL719 and Capecitabine in Patients With Metastatic Breast Cancer","source_id_and_acronym":"NCT01300962","lead_sponsor":"UNC Lineberger Comprehensive Cancer Center","biomarkers":" HER-2","pipe":"","alterations":" ","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • lapatinib • capecitabine • Piqray (alpelisib) • buparlisib (AN2025)"],"overall_status":"Completed","enrollment":" Enrollment 47","initiation":"Initiation: 08/01/2011","start_date":" 08/01/2011","primary_txt":" Primary completion: 02/07/2017","primary_completion_date":" 02/07/2017","study_txt":" Completion: 12/31/2018","study_completion_date":" 12/31/2018","last_update_posted":"2023-12-04"},{"id":"24489ba0-71ab-4e09-843d-98fd4f7dee61","acronym":"","url":"https://clinicaltrials.gov/study/NCT01591421","created_at":"2021-01-18T06:47:44.143Z","updated_at":"2024-07-02T16:35:41.019Z","phase":"Phase 1/2","brief_title":"P13Kinase Inhibitor BKM120 in Combination With Panitumumab in Metastatic/Advanced RAS-Wild Type Colorectal Cancer.","source_id_and_acronym":"NCT01591421","lead_sponsor":"Canadian Cancer Trials Group","biomarkers":" KRAS • RAS","pipe":" | ","alterations":" KRAS mutation • RAS mutation • RAS wild-type","tags":["KRAS • RAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • RAS mutation • RAS wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Vectibix (panitumumab) • buparlisib (AN2025)"],"overall_status":"Completed","enrollment":" Enrollment 22","initiation":"Initiation: 09/06/2012","start_date":" 09/06/2012","primary_txt":" Primary completion: 09/30/2015","primary_completion_date":" 09/30/2015","study_txt":" Completion: 11/12/2019","study_completion_date":" 11/12/2019","last_update_posted":"2023-08-04"},{"id":"545f611b-d0e7-4dc8-b77f-b44dd66b09fc","acronym":"","url":"https://clinicaltrials.gov/study/NCT01971489","created_at":"2021-01-18T08:58:09.753Z","updated_at":"2024-07-02T16:35:49.427Z","phase":"Phase 1","brief_title":"Buparlisib, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Advanced Solid Tumors","source_id_and_acronym":"NCT01971489","lead_sponsor":"Roswell Park Cancer Institute","biomarkers":" PIK3CA","pipe":" | ","alterations":" PIK3CA mutation","tags":["PIK3CA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PIK3CA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • gemcitabine • buparlisib (AN2025)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 09/01/2015","start_date":" 09/01/2015","primary_txt":" Primary completion: 08/01/2016","primary_completion_date":" 08/01/2016","study_txt":"","study_completion_date":"","last_update_posted":"2023-04-27"},{"id":"cfeafed8-eac2-4080-8319-5309f6abc822","acronym":"","url":"https://clinicaltrials.gov/study/NCT02049541","created_at":"2021-01-18T09:25:29.420Z","updated_at":"2025-02-25T15:41:18.938Z","phase":"Phase 1","brief_title":"Study of BKM120 \u0026 Rituximab in Patients With Relapsed or Refractory Indolent B-Cell Lymphoma","source_id_and_acronym":"NCT02049541","lead_sponsor":"Kami Maddocks, MD","biomarkers":" CCND1","pipe":" | ","alterations":" CCND1 overexpression","tags":["CCND1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CCND1 overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • buparlisib (AN2025)"],"overall_status":"Completed","enrollment":" Enrollment 18","initiation":"Initiation: 07/21/2014","start_date":" 07/21/2014","primary_txt":" Primary completion: 09/12/2018","primary_completion_date":" 09/12/2018","study_txt":" Completion: 04/09/2019","study_completion_date":" 04/09/2019","last_update_posted":"2022-06-30"},{"id":"5e26e90d-9170-4e9e-aa8c-1b64bfb3c650","acronym":"","url":"https://clinicaltrials.gov/study/NCT02000882","created_at":"2021-01-18T09:08:04.339Z","updated_at":"2025-02-25T15:41:08.964Z","phase":"Phase 2","brief_title":"STAR Cape+BKM120 MBC With Brain Met","source_id_and_acronym":"NCT02000882","lead_sponsor":"US Oncology Research","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" HER-2 positive • HER-2 negative • ER negative","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HER-2 negative • ER negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • capecitabine • buparlisib (AN2025)"],"overall_status":"Completed","enrollment":" Enrollment 10","initiation":"Initiation: 05/29/2014","start_date":" 05/29/2014","primary_txt":" Primary completion: 03/29/2019","primary_completion_date":" 03/29/2019","study_txt":" Completion: 03/29/2019","study_completion_date":" 03/29/2019","last_update_posted":"2022-02-07"},{"id":"922ea0fb-ea5e-446c-88d6-9339060eab6b","acronym":"","url":"https://clinicaltrials.gov/study/NCT01816984","created_at":"2021-01-18T08:04:06.543Z","updated_at":"2024-07-02T16:36:23.449Z","phase":"Phase 1/2","brief_title":"PI3K Inhibitor BKM120 and Cetuximab in Treating Patients With Recurrent or Metastatic Head and Neck Cancer","source_id_and_acronym":"NCT01816984","lead_sponsor":"University of Chicago","biomarkers":" EGFR","pipe":"","alterations":" ","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Erbitux (cetuximab) • cisplatin • buparlisib (AN2025)"],"overall_status":"Completed","enrollment":" Enrollment 12","initiation":"Initiation: 05/01/2013","start_date":" 05/01/2013","primary_txt":" Primary completion: 04/01/2018","primary_completion_date":" 04/01/2018","study_txt":" Completion: 09/01/2020","study_completion_date":" 09/01/2020","last_update_posted":"2021-10-05"},{"id":"cbf09b9b-a2c0-4dc6-a145-f3dcbb85965c","acronym":"","url":"https://clinicaltrials.gov/study/NCT01623349","created_at":"2021-01-18T06:57:53.787Z","updated_at":"2025-02-25T15:05:16.877Z","phase":"Phase 1","brief_title":"Phase I Study of the Oral PI3kinase Inhibitor BKM120 or BYL719 and the Oral PARP Inhibitor Olaparib in Patients With Recurrent Triple Negative Breast Cancer or High Grade Serous Ovarian Cancer","source_id_and_acronym":"NCT01623349","lead_sponsor":"Dana-Farber Cancer Institute","biomarkers":" BRCA1 • BRCA","pipe":" | ","alterations":" BRCA2 mutation • BRCA1 mutation • BRCA1 mutation + BRCA2 mutation","tags":["BRCA1 • BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA2 mutation • BRCA1 mutation • BRCA1 mutation + BRCA2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • Piqray (alpelisib) • buparlisib (AN2025)"],"overall_status":"Completed","enrollment":" Enrollment 118","initiation":"Initiation: 09/01/2012","start_date":" 09/01/2012","primary_txt":" Primary completion: 05/01/2019","primary_completion_date":" 05/01/2019","study_txt":" Completion: 12/01/2020","study_completion_date":" 12/01/2020","last_update_posted":"2021-02-10"},{"id":"7430207d-eb08-42c6-b5f0-7c6611efc9b3","acronym":"LeeBLet","url":"https://clinicaltrials.gov/study/NCT02154776","created_at":"2021-01-18T10:01:18.479Z","updated_at":"2024-07-02T16:36:37.104Z","phase":"Phase 1","brief_title":"Dose Escalation Study of LEE011 in Combination With Buparlisib and Letrozole in HR+, HER2-negative Post-menopausal Women With Advanced Breast Cancer.","source_id_and_acronym":"NCT02154776 - LeeBLet","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" ER positive • HER-2 negative • PGR positive","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 negative • PGR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Kisqali (ribociclib) • letrozole • buparlisib (AN2025)"],"overall_status":"Completed","enrollment":" Enrollment 13","initiation":"Initiation: 06/27/2014","start_date":" 06/27/2014","primary_txt":" Primary completion: 10/26/2016","primary_completion_date":" 10/26/2016","study_txt":" Completion: 10/26/2016","study_completion_date":" 10/26/2016","last_update_posted":"2020-12-19"},{"id":"dcfdfb8d-1bd6-45ea-82d2-226512a2eba5","acronym":"","url":"https://clinicaltrials.gov/study/NCT01576666","created_at":"2021-01-18T06:42:34.232Z","updated_at":"2024-07-02T16:36:37.119Z","phase":"Phase 1","brief_title":"Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors","source_id_and_acronym":"NCT01576666","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" HER-2 • PGR","pipe":" | ","alterations":" HR positive","tags":["HER-2 • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e buparlisib (AN2025) • Odomzo (sonidegib)"],"overall_status":"Completed","enrollment":" Enrollment 120","initiation":"Initiation: 07/01/2012","start_date":" 07/01/2012","primary_txt":" Primary completion: 04/01/2015","primary_completion_date":" 04/01/2015","study_txt":" Completion: 04/01/2015","study_completion_date":" 04/01/2015","last_update_posted":"2020-12-19"},{"id":"c850f34e-9f94-4249-8ffe-e1e3fadb3270","acronym":"","url":"https://clinicaltrials.gov/study/NCT02088684","created_at":"2021-01-17T17:48:26.747Z","updated_at":"2024-07-02T16:36:37.196Z","phase":"Phase 1","brief_title":"Study of LEE011 With Fulvestrant and BYL719 or BKM120 in Advanced Breast Cancer","source_id_and_acronym":"NCT02088684","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" HER-2","pipe":" | ","alterations":" HR positive • HER-2 negative","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HR positive • HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Piqray (alpelisib) • Kisqali (ribociclib) • fulvestrant • buparlisib (AN2025)"],"overall_status":"Completed","enrollment":" Enrollment 70","initiation":"Initiation: 05/19/2014","start_date":" 05/19/2014","primary_txt":" Primary completion: 04/17/2018","primary_completion_date":" 04/17/2018","study_txt":" Completion: 04/17/2018","study_completion_date":" 04/17/2018","last_update_posted":"2020-12-17"},{"id":"1c51c34e-b0e4-4282-8dd9-55eb5e71d87e","acronym":"","url":"https://clinicaltrials.gov/study/NCT01285466","created_at":"2021-01-18T05:12:58.574Z","updated_at":"2024-07-02T16:36:37.611Z","phase":"Phase 1","brief_title":"A Trial of Oral BEZ235 and BKM120 in Combination With Paclitaxel With or Without Trastuzumab","source_id_and_acronym":"NCT01285466","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" HER-2","pipe":"","alterations":" ","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • paclitaxel • dactolisib (RTB101) • buparlisib (AN2025)"],"overall_status":"Completed","enrollment":" Enrollment 110","initiation":"Initiation: 01/01/2011","start_date":" 01/01/2011","primary_txt":" Primary completion: 10/01/2014","primary_completion_date":" 10/01/2014","study_txt":" Completion: 10/01/2014","study_completion_date":" 10/01/2014","last_update_posted":"2020-12-09"},{"id":"bd221991-838b-48d4-9b16-c1017bc662e5","acronym":"","url":"https://clinicaltrials.gov/study/NCT01155453","created_at":"2021-01-18T04:36:03.283Z","updated_at":"2024-07-02T16:36:37.621Z","phase":"Phase 1","brief_title":"A Study to Investigate Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) of BKM120 Plus GSK1120212 in Selected Advanced Solid Tumor Patients","source_id_and_acronym":"NCT01155453","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mekinist (trametinib) • buparlisib (AN2025)"],"overall_status":"Completed","enrollment":" Enrollment 113","initiation":"Initiation: 04/01/2010","start_date":" 04/01/2010","primary_txt":" Primary completion: 11/01/2014","primary_completion_date":" 11/01/2014","study_txt":" Completion: 11/01/2014","study_completion_date":" 11/01/2014","last_update_posted":"2020-12-09"},{"id":"46fd06e2-22d2-4618-8f96-abe73ac96311","acronym":"SOLTI-1103","url":"https://clinicaltrials.gov/study/NCT01629615","created_at":"2021-01-17T17:12:20.884Z","updated_at":"2025-02-25T15:52:49.963Z","phase":"Phase 2","brief_title":"A Trial of BKM120 (a PI3K Inhibitor) in Patients With Triple Negative Metastatic Breast Cancer","source_id_and_acronym":"NCT01629615 - SOLTI-1103","lead_sponsor":"SOLTI Breast Cancer Research Group","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" HER-2 negative • ER negative","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • ER negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e buparlisib (AN2025)"],"overall_status":"Completed","enrollment":" Enrollment 50","initiation":"Initiation: 06/01/2012","start_date":" 06/01/2012","primary_txt":" Primary completion: 10/01/2015","primary_completion_date":" 10/01/2015","study_txt":" Completion: 10/01/2015","study_completion_date":" 10/01/2015","last_update_posted":"2020-10-28"},{"id":"b34e10f2-e828-43d8-8876-c7e18bd14839","acronym":"","url":"https://clinicaltrials.gov/study/NCT01363232","created_at":"2021-01-18T05:34:52.864Z","updated_at":"2024-07-02T16:36:40.417Z","phase":"Phase 1","brief_title":"Safety, Pharmacokinetics and Pharmacodynamics of BKM120 Plus MEK162 in Selected Advanced Solid Tumor Patients","source_id_and_acronym":"NCT01363232","lead_sponsor":"Array Biopharma, now a wholly owned subsidiary of Pfizer","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mektovi (binimetinib) • buparlisib (AN2025)"],"overall_status":"Completed","enrollment":" Enrollment 89","initiation":"Initiation: 08/01/2011","start_date":" 08/01/2011","primary_txt":" Primary completion: 03/01/2014","primary_completion_date":" 03/01/2014","study_txt":" Completion: 12/18/2017","study_completion_date":" 12/18/2017","last_update_posted":"2020-10-05"},{"id":"c1924624-7573-4ba0-bec2-9619777dfc8f","acronym":"BELLE-2","url":"https://clinicaltrials.gov/study/NCT01610284","created_at":"2021-01-18T06:53:40.260Z","updated_at":"2024-07-02T16:36:41.686Z","phase":"Phase 3","brief_title":"Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor","source_id_and_acronym":"NCT01610284 - BELLE-2","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" HER-2 • PI3K","pipe":" | ","alterations":" HR positive • HER-2 negative","tags":["HER-2 • PI3K"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HR positive • HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e fulvestrant • buparlisib (AN2025)"],"overall_status":"Completed","enrollment":" Enrollment 1147","initiation":"Initiation: 08/07/2012","start_date":" 08/07/2012","primary_txt":" Primary completion: 04/29/2015","primary_completion_date":" 04/29/2015","study_txt":" Completion: 04/19/2019","study_completion_date":" 04/19/2019","last_update_posted":"2020-08-25"},{"id":"d062715d-8b8f-42f1-b506-2bb552d640b0","acronym":"","url":"https://clinicaltrials.gov/study/NCT01512251","created_at":"2021-01-18T06:21:22.749Z","updated_at":"2025-02-25T15:52:29.232Z","phase":"Phase 1/2","brief_title":"BKM120 Combined With Vemurafenib (PLX4032) in BRAFV600E/K Mutant Advanced Melanoma","source_id_and_acronym":"NCT01512251","lead_sponsor":"University of California, San Francisco","biomarkers":" PTEN","pipe":" | ","alterations":" BRAF V600E • BRAF V600 • BRAF V600K","tags":["PTEN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • BRAF V600 • BRAF V600K"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zelboraf (vemurafenib) • buparlisib (AN2025)"],"overall_status":"Completed","enrollment":" Enrollment 8","initiation":"Initiation: 06/09/2012","start_date":" 06/09/2012","primary_txt":" Primary completion: 12/13/2013","primary_completion_date":" 12/13/2013","study_txt":" Completion: 03/21/2017","study_completion_date":" 03/21/2017","last_update_posted":"2020-08-17"},{"id":"b8048913-d20b-4906-a3da-fd90e1d02a1c","acronym":"B-YOND","url":"https://clinicaltrials.gov/study/NCT02058381","created_at":"2021-01-18T09:28:18.645Z","updated_at":"2024-07-02T16:36:49.010Z","phase":"Phase 1","brief_title":"A Phase Ib Dose De-escalation Study With BYL719 in Premenopausal Patients With Locally Advanced or Metastatic Breast Cancer","source_id_and_acronym":"NCT02058381 - B-YOND","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" ER positive • HR positive • HER-2 negative • PGR positive","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HR positive • HER-2 negative • PGR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e tamoxifen • Piqray (alpelisib) • buparlisib (AN2025) • goserelin acetate"],"overall_status":"Completed","enrollment":" Enrollment 40","initiation":"Initiation: 05/06/2014","start_date":" 05/06/2014","primary_txt":" Primary completion: 06/19/2018","primary_completion_date":" 06/19/2018","study_txt":" Completion: 06/19/2018","study_completion_date":" 06/19/2018","last_update_posted":"2020-03-09"},{"id":"2b092fd3-dadb-42dc-a9d2-ad094859b4e3","acronym":"NeoPHOEBE","url":"https://clinicaltrials.gov/study/NCT01816594","created_at":"2021-01-18T08:03:59.157Z","updated_at":"2024-07-02T16:36:53.700Z","phase":"Phase 2","brief_title":"NeoPHOEBE: Neoadjuvant Trastuzumab + BKM120 in Combination With Weekly Paclitaxel in HER2-positive Primary Breast Cancer","source_id_and_acronym":"NCT01816594 - NeoPHOEBE","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" HER-2 • ER • PIK3CA","pipe":" | ","alterations":" HER-2 positive • PIK3CA mutation • ER negative • PIK3CA wild-type","tags":["HER-2 • ER • PIK3CA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • PIK3CA mutation • ER negative • PIK3CA wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • paclitaxel • buparlisib (AN2025)"],"overall_status":"Completed","enrollment":" Enrollment 50","initiation":"Initiation: 09/03/2013","start_date":" 09/03/2013","primary_txt":" Primary completion: 02/18/2015","primary_completion_date":" 02/18/2015","study_txt":" Completion: 02/18/2015","study_completion_date":" 02/18/2015","last_update_posted":"2019-11-14"},{"id":"cb1cf64e-efc9-40b7-af57-995830e5f6b5","acronym":"PIK-ORL","url":"https://clinicaltrials.gov/study/NCT01737450","created_at":"2021-01-18T07:36:02.285Z","updated_at":"2024-07-02T16:36:58.701Z","phase":"Phase 2","brief_title":"Activity and Safety Study of BKM120 in Monotherapy in Patient With Metastatic Head and Neck Cancer Recurrent or Progressive","source_id_and_acronym":"NCT01737450 - PIK-ORL","lead_sponsor":"Centre Leon Berard","biomarkers":" PIK3CA","pipe":" | ","alterations":" PIK3CA mutation","tags":["PIK3CA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PIK3CA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Erbitux (cetuximab) • buparlisib (AN2025)"],"overall_status":"Completed","enrollment":" Enrollment 58","initiation":"Initiation: 01/01/2013","start_date":" 01/01/2013","primary_txt":" Primary completion: 09/01/2018","primary_completion_date":" 09/01/2018","study_txt":" Completion: 03/01/2019","study_completion_date":" 03/01/2019","last_update_posted":"2019-06-24"},{"id":"49fbcf0e-3fee-49ef-aec1-7156d3fe1d8f","acronym":"","url":"https://clinicaltrials.gov/study/NCT01339052","created_at":"2021-01-18T05:27:46.917Z","updated_at":"2025-02-25T15:51:51.879Z","phase":"Phase 2","brief_title":"Phase II Study of BKM120 for Subjects With Recurrent Glioblastoma","source_id_and_acronym":"NCT01339052","lead_sponsor":"Patrick Y. Wen, MD","biomarkers":" PIK3CA • PTEN • PIK3R1","pipe":" | ","alterations":" PIK3CA mutation • PTEN deletion • PTEN mutation","tags":["PIK3CA • PTEN • PIK3R1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PIK3CA mutation • PTEN deletion • PTEN mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e buparlisib (AN2025)"],"overall_status":"Completed","enrollment":" Enrollment 65","initiation":"Initiation: 09/01/2011","start_date":" 09/01/2011","primary_txt":" Primary completion: 10/01/2016","primary_completion_date":" 10/01/2016","study_txt":" Completion: 02/01/2019","study_completion_date":" 02/01/2019","last_update_posted":"2019-03-19"},{"id":"cda106cd-045e-456f-8140-030b6df46879","acronym":"","url":"https://clinicaltrials.gov/study/NCT01923168","created_at":"2021-01-18T08:40:53.958Z","updated_at":"2024-07-02T16:37:06.879Z","phase":"Phase 2","brief_title":"Study of Letrozole With or Without BYL719 or Buparlisib, for the Neoadjuvant Treatment of Postmenopausal Women","source_id_and_acronym":"NCT01923168","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" HER-2 • ER • PIK3CA","pipe":" | ","alterations":" HER-2 negative • PIK3CA mutation • PIK3CA wild-type","tags":["HER-2 • ER • PIK3CA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • PIK3CA mutation • PIK3CA wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Piqray (alpelisib) • letrozole • buparlisib (AN2025)"],"overall_status":"Completed","enrollment":" Enrollment 340","initiation":"Initiation: 03/11/2014","start_date":" 03/11/2014","primary_txt":" Primary completion: 07/07/2017","primary_completion_date":" 07/07/2017","study_txt":" Completion: 07/08/2017","study_completion_date":" 07/08/2017","last_update_posted":"2018-09-14"},{"id":"ef6babad-cb08-4d51-ae0f-8ee57b90a4d7","acronym":"PIKTAM","url":"https://clinicaltrials.gov/study/NCT02404844","created_at":"2021-01-18T11:28:56.980Z","updated_at":"2025-02-25T15:42:21.807Z","phase":"Phase 2","brief_title":"Trial of BKM120/Tamoxifen-combination in Patients With HR-pos, HER2-neg Breast Cancer","source_id_and_acronym":"NCT02404844 - PIKTAM","lead_sponsor":"University Hospital, Essen","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" HR positive • HER-2 negative • PGR positive","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HR positive • HER-2 negative • PGR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e tamoxifen • buparlisib (AN2025)"],"overall_status":"Completed","enrollment":" Enrollment 48","initiation":"Initiation: 12/01/2014","start_date":" 12/01/2014","primary_txt":" Primary completion: 09/19/2017","primary_completion_date":" 09/19/2017","study_txt":" Completion: 10/19/2017","study_completion_date":" 10/19/2017","last_update_posted":"2018-04-20"},{"id":"7edccb49-0785-4c46-83e6-3209038aea5b","acronym":"","url":"https://clinicaltrials.gov/study/NCT01297452","created_at":"2021-01-18T05:16:25.299Z","updated_at":"2025-02-25T15:51:41.758Z","phase":"Phase 1","brief_title":"BKM120 + Carboplatin + Paclitaxel for Patients With Advanced Solid Tumors","source_id_and_acronym":"NCT01297452","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" PTEN","pipe":" | ","alterations":" PTEN deletion • PTEN mutation","tags":["PTEN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PTEN deletion • PTEN mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • paclitaxel • buparlisib (AN2025)"],"overall_status":"Completed","enrollment":" Enrollment 45","initiation":"Initiation: 02/15/2011","start_date":" 02/15/2011","primary_txt":" Primary completion: 03/29/2017","primary_completion_date":" 03/29/2017","study_txt":" Completion: 03/29/2017","study_completion_date":" 03/29/2017","last_update_posted":"2017-03-31"},{"id":"b6dfc4a4-9444-4afb-ba81-847d531a5a05","acronym":"PIKHER2","url":"https://clinicaltrials.gov/study/NCT01589861","created_at":"2021-01-18T06:47:09.000Z","updated_at":"2024-07-02T16:37:24.069Z","phase":"Phase 1/2","brief_title":"Safety and Efficacy of BKM120 and Lapatinib in HER2+/PI3K-activated, Trastuzumab-resistant Advanced Breast Cancer","source_id_and_acronym":"NCT01589861 - PIKHER2","lead_sponsor":"Institut Paoli-Calmettes","biomarkers":" HER-2 • PIK3CA • PTEN","pipe":" | ","alterations":" HER-2 positive • PIK3CA mutation • PTEN mutation • AKT1 overexpression • PIK3CA expression • PIK3CA overexpression • PTEN negative","tags":["HER-2 • PIK3CA • PTEN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • PIK3CA mutation • PTEN mutation • AKT1 overexpression • PIK3CA expression • PIK3CA overexpression • PTEN negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • lapatinib • buparlisib (AN2025)"],"overall_status":"Suspended","enrollment":" Enrollment 106","initiation":"Initiation: 12/01/2011","start_date":" 12/01/2011","primary_txt":" Primary completion: 01/01/2018","primary_completion_date":" 01/01/2018","study_txt":" Completion: 01/01/2018","study_completion_date":" 01/01/2018","last_update_posted":"2017-03-28"}]